Lonza, a leading Swiss pharmaceutical company, has revised its financial guidance for 2023, citing lower demand for early-stage services and nutraceutical capsules. The company lowered its sales target and core Ebitda margin, reflecting the current market dynamics that are impacting demand. Lonza is a global leader in contract development and manufacturing, providing services to the pharmaceutical, biotech, and nutrition sectors. The company’s services range from … Continue reading Lonza Adjusts Financial Forecast Amid Lower Demand